Estradiol cypionate/testosterone cypionate

Not to be confused with Depo-Estradiol, Femandren M, or Folivirin.

Estradiol cypionate /
testosterone cypionate

Estradiol cypionate (top) and testosterone cypionate (bottom)
Combination of
Estradiol cypionate	Estrogen
Testosterone cypionate	Androgen; Anabolic steroid
Clinical data
Trade names	Depo-Testadiol, Femovirin, depAndrogyn, others
Other names	EC/TC
Routes of administration	Intramuscular injection
Identifiers
CAS Number	8055-33-2

Estradiol cypionate/testosterone cypionate (EC/TC), sold under the brand names Depo-Testadiol and Femovirin among others, is an injectable combination medication of estradiol cypionate (EC), an estrogen, and testosterone cypionate (TC), an androgen/anabolic steroid, which is used in menopausal hormone therapy for women. ^[1] It is specifically indicated for the treatment of moderate-to-severe vasomotor symptoms (i.e., hot flashes), but can also be used for other estrogen indications in women. ^[1] The medication has also been used to suppress lactation in postpartum women. ^[2]

Depo-Testadiol was provided in the form of 10 mL vials containing 2 mg/mL EC and 50 mg/mL TC in an oil solution and was administered by intramuscular injection once every 4 weeks. ^[1] Conversely, Femovirin was provided in the form of 1 mL ampoules containing 3.5 mg/mL EC (2.4 mg/mL free estradiol) and 90 mg/mL TC (62.9 mg/mL free testosterone) in an oil solution and was administered by intramuscular injection once every 4 to 6 weeks. ^[3]

^{[4] [5] [6] [7]} The elimination half-life of EC in oil by intramuscular injection is approximately 5 days, while the elimination half-life of TC in oil by intramuscular injection is approximately 8 days. ^[1] EC/TP reportedly has a duration of about 21 days. ^[8]

EC/TC likely poses a considerably increased risk of endometrial hyperplasia and cancer in women with intact uteruses (i.e., women who are not hysterectomized) if it is not combined with a progestogen. ^[1] This is due to the EC component. ^[1] The concomitant use of a progestogen will abolish such risks. ^[1] The medication can also cause masculinization, such as acne, deepened voice, hirsutism, and increased sex drive, due to its TC component. ^[1] Some of these masculinizing symptoms, such as voice deepening, can be irreversible. ^[1]

Depo-Testadiol was introduced for medical use in 1954, ^[9] while Femovirin was introduced for medical use in 1956. ^[10] An oral tablet product with the same brand name of Femovirin, containing ethinylestradiol and methyltestosterone, was marketed in 1958, and should not be confused with the injectable Femovirin. ^{[11] [4]} Depo-Testadiol was discontinued in the United States by 2013. ^[12] Both Depo-Testadiol and Femovirin have been discontinued in most other countries, but formulations of EC/TC under other brand names continue to be marketed in Taiwan. ^{[13] [14] [15]}

• v
• t
• e

Androgen replacement therapy formulations and dosages used in women

Route	Medication	Major brand names	Form	Dosage
Oral	Testosterone undecanoate	Andriol, Jatenzo	Capsule	40–80 mg 1x/1–2 days
	Methyltestosterone	Metandren, Estratest	Tablet	0.5–10 mg/day
	Fluoxymesterone	Halotestin	Tablet	1–2.5 mg 1x/1–2 days
	Normethandrone a	Ginecoside	Tablet	5 mg/day
	Tibolone	Livial	Tablet	1.25–2.5 mg/day
	Prasterone (DHEA) b	–	Tablet	10–100 mg/day
Sublingual	Methyltestosterone	Metandren	Tablet	0.25 mg/day
Transdermal	Testosterone	Intrinsa	Patch	150–300 μg/day
		AndroGel	Gel, cream	1–10 mg/day
Vaginal	Prasterone (DHEA)	Intrarosa	Insert	6.5 mg/day
Injection	Testosterone propionate a	Testoviron	Oil solution	25 mg 1x/1–2 weeks
	Testosterone enanthate	Delatestryl, Primodian Depot	Oil solution	25–100 mg 1x/4–6 weeks
	Testosterone cypionate	Depo-Testosterone, Depo-Testadiol	Oil solution	25–100 mg 1x/4–6 weeks
	Testosterone isobutyrate a	Femandren M, Folivirin	Aqueous suspension	25–50 mg 1x/4–6 weeks
	Mixed testosterone esters	Climacterona	Oil solution	150 mg 1x/4–8 weeks
		Omnadren, Sustanon	Oil solution	50–100 mg 1x/4–6 weeks
	Nandrolone decanoate	Deca-Durabolin	Oil solution	25–50 mg 1x/6–12 weeks
	Prasterone enanthate a	Gynodian Depot	Oil solution	200 mg 1x/4–6 weeks
Implant	Testosterone	Testopel	Pellet	50–100 mg 1x/3–6 months
Notes: Premenopausal women produce about 230 ± 70 μg testosterone per day (6.4 ± 2.0 mg testosterone per 4 weeks), with a range of 130 to 330 μg per day (3.6–9.2 mg per 4 weeks). Footnotes:a = Mostly discontinued or unavailable. b = Over-the-counter. Sources: See template.

See also

• List of combined sex-hormonal preparations

References

1. "Depo-Testadiol® testosterone cypionate– estradiol cypionate injection". CiteSeerX   10.1.1.703.5708 .
2. Vorherr H (July 1972). "Suppression of postpartum lactation". Postgraduate Medicine. 52 (1): 145–152. doi:10.1080/00325481.1972.11713186. PMID   5037562.
3. Kuhlencordt F, Rausch-Stroomann JG (1959). "Stoffwechsel-Bilanz untersuchungen un Hormontherapie bei verschiedenen Formen der Osteoporose". In Kauffmann F (ed.). Fünfundsechzigster Kongress: Gehalten zu Wiesbaden vom 6.–9. April 1959. Springer-Verlag. pp. 162–166. ISBN   978-3-642-96026-0.
4. Hager HH, Kern W, List PH, Roth HJ (29 July 2013). "Hormone". Hagers Handbuch der Pharmazeutischen Praxis: Für Apotheker, Arzneimittelhersteller, Ärzte und Medizinalbeamte: Wirkstoffgruppen II Chemikalien und Drogen (A-AL). Springer-Verlag. pp. 156, 185. ISBN   978-3-662-25655-8.
5. Saure A (11 November 2013). "Hormonpräparate, die zur Behandlung der Wechseljahre eingesetzt werden". Die Wechseljahre der Frau: Hormone — Präparate — Therapien. Springer-Verlag. pp. 157–. ISBN   978-3-0348-6676-7.
6. Arends G, Zörnig H, Hager H, Frerichs G, Kern W (14 December 2013). "Hormone". Hagers Handbuch der pharmazeutischen Praxis: Für Apotheker, Arzneimittelhersteller, Drogisten, Ärzte u. Medizinalbeamte. Springer-Verlag. pp. 1164–. ISBN   978-3-662-36329-4.
7. Kaiser R (2 July 2013). "Ovar". In Buchborn E, Jahrmärker H, Karl HJ, Martini GA, Müller W, Riecker G, Schwiegk H, Siegenthaler W, Stich W (eds.). Therapie innerer Krankheiten. Springer-Verlag. pp. 405–. ISBN   978-3-662-10489-7.
8. Ufer J (1 January 1978). Hormontherapie in der Frauenheilkunde: Grundlagen und Praxis[Hormone Therapy in Gynecology: Principles and Practice] (in German) (5th ed.). de Gruyter. p. 276. ISBN   978-3110066647. OCLC   924728827.
9. "NEW Prescription Products". Journal of the American Pharmaceutical Association (Practical Pharmacy Ed.). 16 (3): 193–200. 1955. doi:10.1016/S0095-9561(16)33664-7. ISSN   0095-9561.
10. "Neue Spezialitäten". Klinische Wochenschrift. 34 (29–30): 819. 1956. doi:10.1007/BF01468058. ISSN   0023-2173. S2CID   33495393.
11. "Neue Spezialitäten". Klinische Wochenschrift. 36 (24): 1169. 1958. doi:10.1007/BF01481649. ISSN   0023-2173. S2CID   12815948.
12. Food and Drug Administration (2013). "Approved Drug Products with Therapeutic Equivalence Evaluations". FDA Orange Book (33rd ed.). Logos Press. pp. 619–. ISBN   978-1-934899-83-0.
13. "Estradiol". Drugs.com.
14. Sweetman SC, ed. (2009). "Sex hormones and their modulators". Martindale: The Complete Drug Reference (36th ed.). London: Pharmaceutical Press. pp. 2100, 2124–2125. ISBN   978-0-85369-840-1.
15. "IBM Watson Health Products: Please Login". www.micromedexsolutions.com.